Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump's Budget Request To Include ANDA Exclusivity Changes

Executive Summary

180-day exclusivity would begin when a second ANDA is approvable, rather than at first-generic's launch, a potentially major change to the Hatch-Waxman framework if implemented.

You may also be interested in...



Groundhog Day For HHS And Drug Pricing? Why It Might Be Different This Time

President Trump has directed his new HHS Secretary to bring down drug prices – starting 2018 exactly the same way as 2017. But this time it could end differently.

Trump Emphasizes Foreign Drug Prices At Alex Azar's Swearing In

HHS secretary will get US drug prices 'way down … because it’s very unfair to our country,' president says. Also, 'we’re going to be very tough' on drug companies in combating the opioid crisis, Trump says.

New ANDA Review Pathways: Should You Be A Priority Or Expedited?

Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.

Related Content

Topics

UsernamePublicRestriction

Register

GB002280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel